GRI Bio Statistics
Total Valuation
GRI Bio has a market cap or net worth of $3.45 million. The enterprise value is -$4.70 million.
Important Dates
The last earnings date was Friday, January 30, 2026, before market open.
| Earnings Date | Jan 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GRI Bio has 1.45 million shares outstanding.
| Current Share Class | 1.45M |
| Shares Outstanding | 1.45M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +114.34% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 1.12% |
| Float | 1.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.20 |
| P/TBV Ratio | 0.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.25, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.25 |
| Quick Ratio | 3.11 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -238.17% and return on invested capital (ROIC) is -146.35%.
| Return on Equity (ROE) | -238.17% |
| Return on Assets (ROA) | -103.93% |
| Return on Invested Capital (ROIC) | -146.35% |
| Return on Capital Employed (ROCE) | -198.85% |
| Weighted Average Cost of Capital (WACC) | -2.47% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.99M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.05% in the last 52 weeks. The beta is -1.23, so GRI Bio's price volatility has been lower than the market average.
| Beta (5Y) | -1.23 |
| 52-Week Price Change | -99.05% |
| 50-Day Moving Average | 16.91 |
| 200-Day Moving Average | 39.08 |
| Relative Strength Index (RSI) | 21.13 |
| Average Volume (20 Days) | 956,691 |
Short Selling Information
The latest short interest is 700,747, so 48.49% of the outstanding shares have been sold short.
| Short Interest | 700,747 |
| Short Previous Month | 2.69M |
| Short % of Shares Out | 48.49% |
| Short % of Float | 49.97% |
| Short Ratio (days to cover) | 0.15 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.98M |
| Pretax Income | -11.96M |
| Net Income | -11.96M |
| EBITDA | -11.97M |
| EBIT | -11.98M |
| Earnings Per Share (EPS) | -$121.80 |
Full Income Statement Balance Sheet
The company has $8.23 million in cash and $71,000 in debt, with a net cash position of $8.16 million or $5.65 per share.
| Cash & Cash Equivalents | 8.23M |
| Total Debt | 71,000 |
| Net Cash | 8.16M |
| Net Cash Per Share | $5.65 |
| Equity (Book Value) | 6.01M |
| Book Value Per Share | 12.07 |
| Working Capital | 5.95M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$10.19 million and capital expenditures -$3,000, giving a free cash flow of -$10.19 million.
| Operating Cash Flow | -10.19M |
| Capital Expenditures | -3,000 |
| Free Cash Flow | -10.19M |
| FCF Per Share | -$7.05 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GRI Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -346.19% |
| FCF Yield | -295.02% |
Analyst Forecast
The average price target for GRI Bio is $644.00, which is 26,845.61% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $644.00 |
| Price Target Difference | 26,845.61% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 26, 2026. It was a reverse split with a ratio of 1:28.
| Last Split Date | Jan 26, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:28 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |